优化急性诊疗中的抗血小板药物使用:疑似急性冠脉综合征的新干预阈值
该研究通过三项系统评价量化替格瑞洛、氯吡格雷或阿司匹林单药治疗ACS的临床结局及患者偏好权重,构建效用模型模拟不同治疗策略的结局概率,确定各策略优效的ACS概率阈值。在英国两家大型教学医院的前瞻性诊断研究(660例疑似ACS患者,87例(13.2%)确诊ACS)中,用T-MACS模型计算ACS概率进行验证。结果显示ACS概率>8.0%时替格瑞洛联合策略总体获益最大,≤8.0%时单用阿司匹林获益更大。作者认为T-MACS指导的精准抗血小板策略的临床与成本效益有待进一步研究。
要点
- 疑似ACS患者ACS概率>8.0%时,替格瑞洛联合抗血小板策略的净获益大于单用阿司匹林。
- ACS概率≤8.0%时,单用阿司匹林的净获益大于替格瑞洛联合策略。
- 验证队列660例疑似ACS患者中87例(13.2%)确诊ACS,用T-MACS模型计算概率。
- 对>8%概率患者处方联合抗血小板策略的效用大于单用阿司匹林。
- 作者认为该精准医学方法的临床与成本效益有待进一步研究。
适用人群与场景
- 疑似急性冠脉综合征(ACS)患者,急诊科就诊场景。
- 验证研究纳入英国两家大型教学医院(伦敦圣乔治医院2015年10月至2017年6月招募,曼彻斯特皇家医院2015年2月至2017年8月招募)的疑似ACS患者。
诊断标准与关键阈值
- 使用T-MACS(Troponin-only Manchester Acute Coronary Syndromes)临床预测模型计算ACS概率。
- ACS概率>8.0%为替格瑞洛联合抗血小板策略净获益优于单用阿司匹林的阈值。
- ACS诊断基于系列高敏肌钙蛋白检测和30天随访裁定。
处置流程与药物剂量
- 对疑似ACS患者使用T-MACS模型计算ACS概率。
- 当ACS概率>8.0%时,替格瑞洛联合抗血小板策略的总体获益最大,优于单用阿司匹林。
- 当ACS概率≤8.0%时,单用阿司匹林获益大于替格瑞洛联合策略。
研究设计与关键结果
- 研究类型:三项系统评价结合效用模型构建,并在前瞻性诊断研究中验证;系统评价检索截至2017年11月。
- 模型构建基于6项研究的数据,构建了三个模型。
- 替格瑞洛在ACS概率>8.0%时总体获益最大;低于该阈值单用阿司匹林获益更大。
- 验证队列660例疑似ACS患者,87例(13.2%)确诊ACS。
- 对ACS概率>8%的患者处方联合抗血小板策略的效用大于单用阿司匹林。
证据类型、等级与局限
- 证据类型:系统评价结合效用模型构建的前瞻性诊断研究验证。
- 局限:作者指出该精准医学方法的临床与成本效益有待进一步研究(warrants further study)。
对床旁实践的改变
- 作者认为,当T-MACS模型预测ACS概率>8.0%时,替格瑞洛联合抗血小板策略的净获益大于单用阿司匹林。
- 作者认为,当ACS概率≤8.0%时,单用阿司匹林的净获益大于替格瑞洛联合策略。
- 作者认为该精准医学方法的临床与成本效益有待进一步研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To construct a model to optimise and personalise recommendations for antiplatelet prescription for patients with suspected acute coronary syndrome (ACS). Acknowledging that emergency physicians work with diagnostic uncertainty, we sought to identify the point at which the probability of ACS is sufficiently high that the benefits of antiplatelet treatment outweigh the risks. Second, we evaluated the projected clinical impact of this approach by using a clinical prediction model (Troponin-only Manchester Acute Coronary Syndromes (T-MACS)) to calculate the probability of ACS.
METHODS: We conducted three systematic reviews, quantifying the effects of ticagrelor, clopidogrel or aspirin-alone treatment strategies for ACS (November 2017). We extracted data for (a) clinical outcomes and (b) weighted patient preferences (utilities) for each outcome. We then constructed utilitarian models, simulating the probability of clinical outcomes with different treatment strategies. This identified the threshold probability of ACS at which each treatment strategy became superior.We validated this approach in a prospective diagnostic study including patients with suspected ACS that was conducted at two large UK teaching hospitals (St George's Hospital London recruited October 2015 to June 2017 and Manchester Royal Infirmary: February 2015 to August 2017). We calculated the probability of ACS using T-MACS. The diagnosis of ACS was adjudicated based on serial high-sensitivity troponin testing and 30-day follow-up.
RESULTS: We constructed three models using data from six studies. Prescribing ticagrelor had greatest overall benefit when the probability of ACS exceeded 8.0%. Below that threshold, aspirin alone yielded greater benefit. The validation study included 660 patients, of which 87 (13.2%) had ACS. Prescription of combined antiplatelet strategy to patients with >8% probability of ACS had greater utility than aspirin alone.
CONCLUSION: Treatment with ticagrelor appears to yield greater net benefit for patients when the probability of ACS >8%. The clinical and cost-effectiveness of this 'precision medicine' approach warrants further study.
参考来源
- Reynard C, Morris N, Moss P, et al. Optimising antiplatelet utilisation in the acute care setting: a novel threshold for medical intervention in suspected acute coronary syndromes. Emerg Med J. 2019. PMID: 30612091. doi:10.1136/emermed-2018-207633
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。